
MannKind (MNKD) Stock Forecast & Price Target
MannKind (MNKD) Analyst Ratings
Bulls say
MannKind is set for success thanks to strong revenue streams, potential growth from upcoming catalysts, and diversification opportunities from their Technosphere platform and recent acquisition of scPharmaceuticals. Education and marketing initiatives also contribute to the company's growth outlook, with a potential boost from UTHR's confirmation of pursuing Tyvaso DPI for IPF. Risks such as commercial execution, clinical trials, regulatory hurdles, and partnership uncertainties remain, but the company's MNKD-102 product provides a potential backup plan.
Bears say
MannKind is facing significant competition in the diabetes market with its Afrezza product, and the potential success of its other products is uncertain. The company is heavily dependent on its partnerships with other pharmaceutical companies for the commercialization of its products, and its current revenue levels are not sustainable without continued growth and expansion into new markets. Furthermore, MannKind's recent acquisition of scPharmaceuticals adds significant additional financial risk to the company's already unstable financial position. All of these factors contribute to a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.
MannKind (MNKD) Analyst Forecast & Price Prediction
Start investing in MannKind (MNKD)
Order type
Buy in
Order amount
Est. shares
0 shares